Accéder au contenu
Merck

ALOX15-launched PUFA-phospholipids peroxidation increases the susceptibility of ferroptosis in ischemia-induced myocardial damage.

Signal transduction and targeted therapy (2022-08-16)
Xiao-Hui Ma, Jiang-Han-Zi Liu, Chun-Yu Liu, Wan-Yang Sun, Wen-Jun Duan, Guan Wang, Hiroshi Kurihara, Rong-Rong He, Yi-Fang Li, Yang Chen, Hongcai Shang
RÉSUMÉ

Myocardial ischemia/reperfusion (I/R) injury is a classic type of cardiovascular disease characterized by injury to cardiomyocytes leading to various forms of cell death. It is believed that irreversible myocardial damage resulted from I/R occurs due to oxidative stress evoked during the reperfusion phase. Here we demonstrate that ischemia triggers a specific redox reaction of polyunsaturated fatty acids (PUFA)-phospholipids in myocardial cells, which acts as a priming signaling that initiates the outbreak of robust oxidative damage in the reperfusion phase. Using animal and in vitro models, the crucial lipid species in I/R injury were identified to be oxidized PUFAs enriched phosphatidylethanolamines. Using multi-omics, arachidonic acid 15-lipoxygenase-1 (ALOX15) was identified as the primary mediator of ischemia-provoked phospholipid peroxidation, which was further confirmed using chemogenetic approaches. Collectively, our results reveal that ALOX15 induction in the ischemia phase acts as a "burning point" to ignite phospholipid oxidization into ferroptotic signals. This finding characterizes a novel molecular mechanism for myocardial ischemia injury and offers a potential therapeutic target for early intervention of I/R injury.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Lipoxidase from Glycine max (soybean), Type I-B, lyophilized powder, ≥50,000 units/mg solid